Key Takeaways Dupixent sales and Eylea HD growth help counter Eyleas ongoing sales decline.Oncology portfolio grows with new FDA approvals for Lynozyfic and Ordspono.FDA review delays tied to Catalent site issues weigh on Eylea HD and odronextamab.Biotech giant Regeneron’s ((REGN) performance has been pretty ho-hum in the year so far. While Eylea sales continue to be under pressure, affecting the top line, the company finally managed to post revenue growth in the second quarter, giving anxious investors som ...